Navigation Links
Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Date:11/22/2013

ron's products, product candidates, and research and clinical programs now underway or planned, including without limitation sarilumab; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates; ongoing regulatory obligations and oversight impacting Regeneron's research and clinical programs and business; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare, to be cancelled or terminated without any further product success; and risks associated with third party intellectual property and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended Decemb
'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Sanofi US Launches Collaborate Activate Innovation Challenge
3. Sanofi Pasteur to add 2D barcode to six more vaccines
4. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
5. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
6. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
7. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
8. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
9. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
10. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 Stryker brand ambassadors ... week at the 3M Championship Champions Tour event near ... in Blaine . Stryker is the official joint ... Starting Friday, August 1 st through Sunday, August ... Mobility Zone; an on-site joint health destination located in the Pioneer ...
(Date:7/30/2014)... , July 30, 2014 Silicon Valley Bank, ... a study today that examines the merger, acquisition ... device companies.  According to the annual report based on ... potential returns since SVB started tracking the data in ... IPO.  Built on solid healthcare M&A activity over the ...
(Date:7/30/2014)... YORK , July 30, 2014 ACCESS ... for oncology supportive care, announced that its novel product ... in an article on OncLive.com titled, "Study Finds Mouth ... Cancers."  Dr. Steve Sonis , a leading expert ... seen in the oncology community for evidence-based strategies for ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3
... the global leader in technology support and BPO services ... today the opening of its new Global Operations Center ... city of Dalian, will specialize in providing services in ... sponsors and clinical research organizations. With dramatic ...
... ARBOR, Mich., April 7, 2011 Adeona Pharmaceuticals, Inc. (AMEX: ... serious central nervous system diseases, announced today that it has ... its common stock at approximately $2.0725 per share to a ... million in gross proceeds. The investor will also receive warrants ...
Cached Medicine Technology:C3i Opens Asia Language Center in Dalian, China 2Adeona to Raise $3.5 Million in Registered Direct Offering 2Adeona to Raise $3.5 Million in Registered Direct Offering 3
(Date:7/30/2014)... The Europe commercial aviation actuation system market ... is expected to reach $1,686.72 million by 2019 at ... an exclusive range of opportunities and challenges which will ... has seen slumps in the past, yet the sector ... to its long-term growth rate of approximately 5 % ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Foot ... Seminar schedule, a series highlighted by eight speakers, 29 ... from seven chiropractic colleges. The seminars cover a range ... from low back stabilization to imaging. The Foot ... professionals by providing informative, entertaining courses that also offer ...
(Date:7/30/2014)... N.J. The household income of its residents is ... or low rates of avoidable hospital visits conditions that ... health care settings if treated at an early stage, according ... State Health Policy (CSHP). , An analysis of hospital ... low-income communities in New Jersey found that as an area,s ...
(Date:7/30/2014)... It is said that necessity is the ... true as a product sponsor for Lash Wars 2014 ... past June. , Lash Affair believes in the ... the eyelash industry through collaboration so Jenelle Paris, Founder and ... NEESA ’s event. Lash Affair’s mission dovetails nicely with ...
(Date:7/30/2014)... one in every twenty elderly American adults is being ... This burgeoning public health crisis especially affects poor and ... makers, researchers, and any citizen who cares about the ... Peterson of Weill Cornell Medical College in the US. ... on elder abuse, the findings of which appear in ...
Breaking Medicine News(10 mins):Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Aviation Actuation System Market is Expected to Reach $1,686.72 Million in 2019 - New Report by MicroMarket Monitor 4Health News:Foot Levelers Announces 2014 Fall Seminars Series Schedule 2Health News:Income is a major driver of avoidable hospitalizations across New Jersey 2Health News:Income is a major driver of avoidable hospitalizations across New Jersey 3Health News:Lash Affair Launches a New Product as Sponsor of the First U.S. Lash Extension Competition 2Health News:Older adults are at risk of financial abuse 2
... International SOS Assistance, Inc. today was awarded the ... Department of Defense TRICARE Overseas Program. Since 1998, International SOS ... and their families receive the highest quality care, no matter ... States and Puerto Rico. , Under this new ...
... given early in pregnancy might save infants most at ... -- U.S. researchers are testing a new approach in ... while they,re still in the womb. , The new ... cells that have been treated to speed and improve ...
... 16 The National Trauma Institute, a national non-profit ... States, announced its first Request for Proposals (RFP) for ... practice and save lives. , The organization will award ... take place in 2010. "Historically, trauma research has been ...
... THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Oct. 16 ... PFE ), today announced new scientific data about ENBREL ... (ACR) Scientific Meeting in Philadelphia, Pa., from Oct. 17-21, ... years of collective clinical experience. , "The ...
... public forum for discussing the latest updates, information on H1N1/Swine flu ... public are invited to submit questions for inclusion in a two-part ... 22, from 10 a.m. - noon on Twitter. , Sandro ... Health System and VA Ann Arbor Healthcare System, will answer questions ...
... comment on media reports this week that France is ... internet, to conform to European rights. Although Budget Minister ... news is disappointing given the drop in heart attack ... Professeur Ph.Gabriel STEG (Universit Paris VII, Centre Hospitalier Bichat-Claude ...
Cached Medicine News:Health News:International SOS Awarded TRICARE Overseas Program Contract 2Health News:Transplant May Treat Metabolic Disorders in Womb 2Health News:National Trauma Institute Announces $600,000 in Funding for Trauma Research 2Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 2Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 3Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 4Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 5Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 6Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 7Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 8Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 9Health News:ESC press statement : Cigarettes on sale on the internet 2Health News:ESC press statement : Cigarettes on sale on the internet 3
... technology makes BURANE XL a ... array of aesthetic laser applications. ... controllable mode for coagulation, an ... procedures, and in particular a ...
... Test is an in vitro immunoassay intended for ... tumor associated antigen. It is indicated for use ... cancer in conjunction with cystoscopy or when prescribed ... by the FDA for prescription home use in ...
Used for measuring rectal pressure during urodynamic studies. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open pack...
Used for cystometry and urethral pressure profilometry. A loop is employed to enhance catheter retention and stabilization within the bladder. Supplied sterile in peel-open packages. Intended for one...
Medicine Products: